Journal of Epilepsy Research · 2018 · 42 citations · 16 references
MedicineNeurosciencePharmacologyEpilepsyNeurochemistryNeuropharmacologyAntiepileptic PharmacologyAntiepileptic PharmacotherapyEpilepsy PathologyNeuroprotectionOxidative Stress In NeurotoxicityAnimal Disease ModelsAnti-apoptotic AgentsAnti-apoptotic BalanceAnti-apoptotic ProteinsBcl-2 Protein ExpressionHistopathological BiomarkersHistopathological EvaluationRodent Epilepsy
BACKGROUND AND PURPOSE: species and has demonstrated beneficial effects in various neurodegenerative disorders in animal models. The objective of this study was to evaluate the antiepileptic, antioxidative, and anti-apoptotic effects of BBR in a pentylenetetrazole (PTZ)-induced kindling model of epilepsy in rats. METHODS: A total of 30 male Wistar rats were randomly assigned to receive BBR (100 mg/kg, oral), sodium valproate (200 mg/kg, i.p.), or saline (0.9% NaCl, i.p.) followed by PTZ (35 mg/kg, i.p.) on alternate days until the animal developed kindling or for 10 weeks. Histopathological examination of the hippocampus; DNA fragmentation study; tests for malondialdehyde, superoxide dismutase, glutathione peroxidase, and reduced glutathione; and gene expression studies (nrf2, bcl-2, bax, and caspase 3) were conducted on whole brain tissue after 10 weeks or kindling. RESULTS: The percentage of kindled animals, histopathological score, malondialdehyde level, and caspase 3 gene expression were significantly lower in the BBR group than in the PTZ group. Superoxide dismutase levels, reduced glutathione levels, and bcl-2 gene expression were significantly higher in the BBR group than in the PTZ group. CONCLUSIONS: The present study demonstrated the anti-epileptogenic effect of BBR, which may be due to antioxidant and anti-apoptotic properties of the PTZ-induced kindling model of epilepsy.
16